You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
|
|---|---|
| Published in |
Journal of Translational Medicine, May 2012
|
| DOI | 10.1186/1479-5876-10-107 |
| Pubmed ID | |
| Authors |
Paolo A Ascierto, Ester Simeone, Diana Giannarelli, Antonio M Grimaldi, Anna Romano, Nicola Mozzillo |
| Abstract |
Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of limited duration. Conversely, responses to ipilimumab take time to develop, but can be durable. Currently, limited data exist on the sequencing of these agents in patients with the BRAFV600 mutation. The aim of this analysis was to identify factors that could potentially be used to optimise the order in which ipilimumab and BRAF inhibitors are administered in this patient population. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Italy | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 1% |
| Ecuador | 1 | 1% |
| United Kingdom | 1 | 1% |
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 66 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 34% |
| Student > Ph. D. Student | 13 | 18% |
| Student > Bachelor | 7 | 10% |
| Other | 5 | 7% |
| Student > Postgraduate | 4 | 6% |
| Other | 14 | 20% |
| Unknown | 4 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 41% |
| Agricultural and Biological Sciences | 18 | 25% |
| Biochemistry, Genetics and Molecular Biology | 8 | 11% |
| Nursing and Health Professions | 2 | 3% |
| Economics, Econometrics and Finance | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 6 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2017.
All research outputs
#5,583,873
of 22,953,506 outputs
Outputs from Journal of Translational Medicine
#860
of 4,010 outputs
Outputs of similar age
#38,584
of 165,654 outputs
Outputs of similar age from Journal of Translational Medicine
#12
of 68 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,010 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,654 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.